RGL-232

RGL-232 is an investigational oncolytic herpes simplex virus type 1 (oHSV-1) therapy developed by Shanghai RGL Pharma and Guangzhou RGL Pharma for the treatment of advanced solid tumors. The virus is genetically engineered to selectively replicate within and destroy cancer cells while sparing normal tissue. To overcome the immunosuppressive tumor microenvironment, RGL-232 is designed to express two potent immune-modulating payloads: human interleukin-12 (hIL-12) and a single-chain variable fragment (scFv) targeting programmed death-ligand 1 (PD-L1). IL-12 promotes the activation and recruitment of T-cells and natural killer (NK) cells, while the PD-L1 scFv blocks the PD-1/PD-L1 checkpoint pathway locally. This dual-payload strategy is intended to stimulate a robust, systemic anti-tumor immune response, potentially turning cold tumors into hot tumors and improving outcomes for patients with refractory solid malignancies.